Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Return on Capital Employed (2018 - 2025)

Historic Return on Capital Employed for Sutro Biopharma (STRO) over the last 8 years, with Q3 2025 value amounting to 1.13%.

  • Sutro Biopharma's Return on Capital Employed fell 7500.0% to 1.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.13%, marking a year-over-year decrease of 7500.0%. This contributed to the annual value of 0.8% for FY2024, which is 5400.0% down from last year.
  • As of Q3 2025, Sutro Biopharma's Return on Capital Employed stood at 1.13%, which was down 7500.0% from 0.94% recorded in Q2 2025.
  • Sutro Biopharma's Return on Capital Employed's 5-year high stood at 0.19% during Q2 2021, with a 5-year trough of 1.13% in Q1 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.38% (2024), whereas its average is 0.48%.
  • As far as peak fluctuations go, Sutro Biopharma's Return on Capital Employed soared by 2900bps in 2021, and later plummeted by -8400bps in 2025.
  • Sutro Biopharma's Return on Capital Employed (Quarter) stood at 0.31% in 2021, then decreased by -22bps to 0.38% in 2022, then soared by 35bps to 0.25% in 2023, then crashed by -232bps to 0.83% in 2024, then tumbled by -36bps to 1.13% in 2025.
  • Its last three reported values are 1.13% in Q3 2025, 0.94% for Q2 2025, and 1.13% during Q1 2025.